8-K: Inhibrx Reports FY25 Results, Advances Clinical Pipeline

Inhibrx Biosciences, Inc. announced its financial results for the fiscal year 2025, highlighting a significant reduction in operating expenses and progress in its clinical programs for ozekibart and INBRX-106.

Summary

• Cash and cash equivalents were $124.2 million as of December 31, 2025.
• The company secured an additional $75.0 million in gross proceeds from a loan amendment on March 18, 2026.
• Research and development (R&D) expenses decreased to $25.3 million in Q4 2025 from $33.4 million in Q4 2024, and to $113.0 million in FY 2025 from $203.7 million in FY 2024.
• General and administrative (G&A) expenses decreased to $5.6 million in Q4 2025 from $16.7 million in Q4 2024, and to $23.3 million in FY 2025 from $127.9 million in FY 2024.
• Net loss for Q4 2025 was $32.8 million, or $2.11 per share, an improvement from a $47.9 million net loss in Q4 2024.
• Net loss for FY 2025 was $140.1 million, or $9.04 per share, compared to a net income of $1.7 billion in FY 2024, which included a one-time gain from the INBRX-101 transaction.
• Upcoming milestones for ozekibart include a Biologics License Application (BLA) submission for chondrosarcoma (early Q2 2026), PFS data for colorectal cancer (Q2 2026), and an FDA meeting for accelerated approval in Ewing Sarcoma and fourth-line colorectal cancer (H2 2026).
• Upcoming milestones for INBRX-106 include interim objective response rate (ORR) data for HNSCC (Q2 2026) and PFS data for HNSCC at ESMO 2026 Congress (Q4 2026).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant cost reductions, an improved net loss in the quarter, and critical upcoming clinical and regulatory milestones, despite continued overall net losses.

Positives

• Significant reduction in R&D expenses in Q4 2025 and FY 2025, primarily due to lower clinical trial costs for ozekibart and decreased contract manufacturing expenses.
• Substantial decrease in G&A expenses in Q4 2025 and FY 2025, mainly due to the conclusion of prior legal proceedings where the company was found not liable for damages, and the absence of one-time transaction costs from the prior year.
• Net loss improved in Q4 2025 to $32.8 million compared to a $47.9 million net loss in Q4 2024.
• Secured an additional $75.0 million in gross proceeds from a loan amendment on March 18, 2026, strengthening the company's cash position.
• Multiple critical clinical milestones are anticipated in 2026, including a BLA submission for ozekibart, indicating significant pipeline progression.

Negatives

• Continued net loss for Q4 2025 ($32.8 million) and FY 2025 ($140.1 million), reflecting ongoing operational expenses typical of a clinical-stage biopharmaceutical company.
• Cash and cash equivalents decreased from $152.6 million at December 31, 2024, to $124.2 million at December 31, 2025, prior to the recent loan proceeds.
• Increased interest expense in FY 2025 ($12.2 million) due to the company's $100.0 million outstanding debt balance, compared to no interest expense in Q4 2024 following debt extinguishment related to the 101 Transaction.
• The substantial net income reported in FY 2024 ($1.7 billion) was primarily a one-time gain from the INBRX-101 transaction and not indicative of ongoing operational profitability.

Risks

• Topline data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, with final data potentially differing materially from topline data.
• Uncertainties regarding the initiation, timing, progress, and results of preclinical studies and clinical trials, and research and development programs.
• Ability to advance therapeutic candidates into, and successfully complete, clinical trials.
• Interpretation of topline, interim, or preliminary data from clinical trials, including interpretations regarding disease control and disease response.
• The company's ability to utilize its technology platform to generate and advance additional therapeutic candidates.
• The scope of protection the company is able to establish and maintain for intellectual property rights covering its therapeutic candidates.
• The ability to raise funds needed to satisfy capital requirements, which may depend on financial, economic, and market conditions and other factors over which the company may have no or limited control.
• The company's financial performance and developments relating to its competitors and its industry.
• Regulatory review and approval of the company's therapeutic candidates.

Future Outlook

Inhibrx expects to submit a Biologics License Application (BLA) for ozekibart for chondrosarcoma early in Q2 2026. The company also plans to announce progression-free survival (PFS) data for ozekibart's colorectal cancer cohort and interim objective response rate (ORR) data for INBRX-106 in head and neck squamous cell carcinoma (HNSCC) in Q2 2026. Further, meetings with the FDA for accelerated approval discussions for ozekibart in Ewing Sarcoma and fourth-line colorectal cancer are planned for H2 2026, and additional INBRX-106 PFS data is expected at ESMO 2026 Congress in Q4 2026.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from company management, beyond listing Kelly D. Deck as Chief Financial Officer and investor/media contact.

Industry Context

StockSavvy.ai notes that Inhibrx operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, where successful advancement of pipeline candidates through regulatory hurdles is critical for valuation. The company's focus on protein engineering and multivalent formats positions it within a specialized segment aiming for optimized therapeutic function. The upcoming BLA submission for ozekibart represents a significant de-risking event, potentially transitioning the company towards commercialization, a key inflection point for clinical-stage firms.

Comparison to Industry Standards

• Clinical-stage biopharmaceutical companies typically face high R&D costs and operate at a net loss until a product achieves market approval and generates significant revenue. Inhibrx's reduced R&D and G&A expenses in FY 2025, while positive, are largely due to the completion of a trial and the absence of one-time transaction costs from the prior year's spin-off, rather than a fundamental shift to profitability.
• Compared to peers like Mirati Therapeutics (acquired by BMS) or Seagen (acquired by Pfizer) at similar clinical stages, Inhibrx's cash position of $124.2 million (plus the recent $75M loan) provides runway, but continued capital raises are common for companies advancing multiple late-stage programs.
• The upcoming BLA submission for ozekibart for chondrosarcoma, a rare cancer, could be a significant milestone, similar to how companies like Blueprint Medicines achieved market entry with targeted therapies for rare indications.

Legal Proceedings

• Legal services incurred in Q4 2024 and FY 2024 in connection with legal proceedings have since concluded.
• The Company was found not liable for damages in these proceedings.

Stakeholder Impact

• Shareholders: Potential positive impact from upcoming clinical milestones and BLA submission, which could drive stock appreciation. Reduced operating expenses and new financing improve financial stability.
• Employees: Continued focus on clinical development suggests stable employment for R&D teams.
• Creditors: The new loan amendment indicates continued access to capital, which is positive for existing creditors.
• Patients: Progress in clinical trials for ozekibart and INBRX-106 offers hope for new therapeutic options in areas like chondrosarcoma, colorectal cancer, Ewing Sarcoma, and HNSCC.

Next Steps

• Submit Biologics License Application (BLA) for ozekibart for unresectable or metastatic conventional chondrosarcoma to the FDA early in Q2 2026.
• Announce progression-free survival (PFS) data for the ozekibart Phase 1/2 colorectal cancer expansion cohort in Q2 2026.
• Meet with the FDA to discuss accelerated approval for ozekibart in Ewing Sarcoma and fourth-line colorectal cancer in H2 2026.
• Announce interim objective response rate (ORR) data from the INBRX-106 randomized Phase 2/3 trial in HNSCC in combination with KEYTRUDA in Q2 2026.
• Announce PFS data from the INBRX-106 randomized Phase 2/3 trial in HNSCC in combination with pembrolizumab in Q4 2026 at the ESMO 2026 Congress.

Key Dates

Recommendation

The company has demonstrated significant progress in cost control and has critical clinical milestones approaching, including a BLA submission. The recent financing also provides a stronger cash runway. However, it remains a clinical-stage company with ongoing net losses and inherent risks associated with drug development and regulatory approvals. The positive developments warrant a "hold" as investors await the outcomes of the announced milestones, which will be key determinants of future valuation.

Keywords

biopharmaceutical, clinical-stage, ozekibart, INBRX-106, chondrosarcoma, colorectal cancer, Ewing Sarcoma, HNSCC, FDA BLA, protein engineering, financial results, R&D expenses, G&A expenses, net loss, Nasdaq: INBX